RAYNER SURGICAL, INC. – Trademark Portfolio

Entity Type: 03

RAYNER SURGICAL, INC. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. The portfolio also extends into Class 36 (Insurance & Financial) across 2 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include OMIDRIA and OMIDRIASSURE. The owner is based in WILMINGTON, DE.

1209 ORANGE STREET

WILMINGTON, DE 19801

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

RAYNER SURGICAL, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (4 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

36
Insurance & Financial (1 filing)

Insurance; financial affairs; monetary affairs; real estate affairs

Frequently Asked Questions

How many trademarks does RAYNER SURGICAL, INC. have?

RAYNER SURGICAL, INC. has 5 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 cancelled.

What trademark classes does RAYNER SURGICAL, INC. file in?

RAYNER SURGICAL, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 36 (Insurance & Financial). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are RAYNER SURGICAL, INC.'s most well-known trademarks?

RAYNER SURGICAL, INC.'s registered trademark portfolio includes well-known marks such as OMIDRIA and OMIDRIASSURE. These are among 4 currently registered trademarks in the portfolio.

What is RAYNER SURGICAL, INC.'s trademark registration success rate?

RAYNER SURGICAL, INC. has a 80% trademark registration rate, with 4 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.